# Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT07214298** · PHASE1,PHASE2 · RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 35 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin Calcium
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Oxaliplatin
- **DRUG:** Pegcetacoplan

## Key facts

- **NCT ID:** NCT07214298
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-16
- **Primary completion:** 2028-02-16
- **Final completion:** 2028-10-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214298, "Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07214298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*